Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -1.05%1.52B | -13.90%329.06M | 23.31%398.19M | 5.97%453.48M | -15.91%336.83M | -21.18%1.53B | -5.41%382.21M | -32.55%322.91M | -26.69%427.94M | -16.39%400.54M |
Operating revenue | -1.05%1.52B | -13.90%329.06M | 23.31%398.19M | 5.97%453.48M | -15.91%336.83M | -21.18%1.53B | -5.41%382.21M | -32.55%322.91M | -26.69%427.94M | -16.39%400.54M |
Cost of revenue | -0.28%1.36B | -12.62%317.76M | 8.29%340.89M | 3.36%372.11M | 1.16%333.86M | -16.10%1.37B | 8.55%363.67M | -29.05%314.79M | -24.50%360.02M | -12.14%330.04M |
Gross profit | -7.36%152.94M | -39.05%11.3M | 605.52%57.3M | 19.79%81.37M | -95.79%2.97M | -47.50%165.09M | -73.14%18.54M | -76.88%8.12M | -36.46%67.92M | -31.83%70.5M |
Operating expense | -1.59%94.02M | -12.46%21.73M | 12.42%24.27M | 1.75%24.43M | -6.06%23.59M | 8.88%95.54M | 9.72%24.83M | -6.43%21.59M | 15.21%24.01M | 18.41%25.11M |
Selling and administrative expenses | -1.59%94.02M | -12.46%21.73M | 12.42%24.27M | 1.75%24.43M | -6.06%23.59M | 8.88%95.54M | 9.72%24.83M | -6.43%21.59M | 15.21%24.01M | 18.41%25.11M |
Operating profit | -15.29%58.91M | -65.96%-10.43M | 345.39%33.04M | 29.66%56.94M | -145.45%-20.63M | -69.32%69.55M | -113.55%-6.29M | -211.69%-13.46M | -48.98%43.91M | -44.79%45.39M |
Net non-operating interest income expense | -51.12%-11.31M | 0.69%-2.17M | -40.92%-2.92M | -79.84%-3.51M | -113.02%-2.7M | -169.15%-7.49M | -186.52%-2.19M | -202.48%-2.08M | -154.10%-1.95M | -125.04%-1.27M |
Non-operating interest expense | 51.12%11.31M | -0.69%2.17M | 40.92%2.92M | 79.84%3.51M | 113.02%2.7M | 169.15%7.49M | 186.52%2.19M | 202.48%2.08M | 154.10%1.95M | 125.04%1.27M |
Other net income (expense) | -128.32%-2.03M | -191.25%-219K | -106.71%-368K | -201.96%-1.35M | -183.33%-90K | 288.81%7.16M | 1,400.00%240K | 293.47%5.49M | 870.35%1.33M | -82.09%108K |
Other non- operating income (expenses) | -128.32%-2.03M | -191.25%-219K | -106.71%-368K | -201.96%-1.35M | -183.33%-90K | 288.81%7.16M | 1,400.00%240K | 293.47%5.49M | 870.35%1.33M | -82.09%108K |
Income before tax | -34.16%45.58M | -55.74%-12.83M | 395.88%29.75M | 20.31%52.07M | -152.94%-23.42M | -69.34%69.22M | -118.04%-8.24M | -178.77%-10.05M | -49.15%43.28M | -46.23%44.23M |
Income tax | -90.23%1.43M | -317.92%-13.18M | 460.26%7.48M | 24.54%13.15M | -164.92%-6.02M | -72.92%14.6M | -126.21%-3.15M | -176.04%-2.08M | -47.12%10.56M | -51.65%9.28M |
Net income | -19.18%44.15M | 106.93%352K | 379.13%22.27M | 18.94%38.93M | -149.77%-17.4M | -68.22%54.62M | -115.11%-5.08M | -179.52%-7.98M | -49.77%32.73M | -44.58%34.95M |
Net income continuous Operations | -19.18%44.15M | 106.93%352K | 379.13%22.27M | 18.94%38.93M | -149.77%-17.4M | -68.22%54.62M | -115.11%-5.08M | -179.52%-7.98M | -49.77%32.73M | -44.58%34.95M |
Minority interest income | ||||||||||
Net income attributable to the parent company | -19.18%44.15M | 106.93%352K | 379.13%22.27M | 18.94%38.93M | -149.77%-17.4M | -68.22%54.62M | -115.11%-5.08M | -179.52%-7.98M | -49.77%32.73M | -44.58%34.95M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | -19.18%44.15M | 106.93%352K | 379.13%22.27M | 18.94%38.93M | -149.77%-17.4M | -68.22%54.62M | -115.11%-5.08M | -179.52%-7.98M | -49.77%32.73M | -44.58%34.95M |
Basic earnings per share | -17.50%1.65 | 105.26%0.01 | 386.21%0.83 | 21.85%1.45 | -151.18%-0.65 | -67.48%2 | -115.57%-0.19 | -180.56%-0.29 | -48.48%1.19 | -43.30%1.27 |
Diluted earnings per share | -16.92%1.62 | 105.26%0.01 | 382.76%0.82 | 23.28%1.43 | -153.28%-0.65 | -67.06%1.95 | -116.10%-0.19 | -182.86%-0.29 | -47.98%1.16 | -43.26%1.22 |
Dividend per share | 4.92%0.64 | 0.00%0.16 | 0.00%0.16 | 10.34%0.16 | 10.34%0.16 | 12.96%0.61 | 10.34%0.16 | 10.34%0.16 | 16.00%0.145 | 16.00%0.145 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |